首页> 外文期刊>African Journal of Pharmacy and Pharmacology >Safety and efficiency of valsartan and combination of valsartan plus hydrochlorothiazide for high blood pressure
【24h】

Safety and efficiency of valsartan and combination of valsartan plus hydrochlorothiazide for high blood pressure

机译:缬沙坦和缬沙坦联合氢氯噻嗪治疗高血压的安全性和有效性

获取原文
           

摘要

The essential?hypertension is one of the most common cardiovascular risk factors in adult population.?The duration of hypertension influences the risk of stroke, heart failure, atherosclerosis, and kidney disease. Diuretics, beta blockers, calcium-antagonists, ACE-inhibitors, and sartans may be used to treat arterial hypertension. In this study, the efficacy and safety of a prompt pharmacologic treatment with valsartan (VAL) or combination of valsartan plus hydrochlorothiazide (VAL/HYCT) in middle aged population was demonstrate with the most frequent cardiovascular risk factors. The results of the 4 months study period showed that treatment with VAL or VAL/HYCT in middle aged 1059 patients significantly reduce the systolic and diastolic blood pressure. Average systolic and diastolic blood pressure were lowered from 161.2 (±16.5) and 92.9 (±9.5) mmHg to 136.1 (±12.5) and 81.6 (±7.8) mmHg, respectively. Side effects were observed only in few patients: elevated serum creatinine (4.6%), elevation of HbA1c (1%) and serum potassium values (0.3%). It may be concluded that VAL or VAL/HYCT is safe and very effective potent antihypertensive drug.
机译:原发性高血压是成人人群中最常见的心血管危险因素之一。高血压的持续时间会影响中风,心力衰竭,动脉粥样硬化和肾脏疾病的风险。利尿剂,β受体阻滞剂,钙拮抗药,ACE抑制剂和沙丁烷可用于治疗高血压。在这项研究中,证实了在中年人群中以缬沙坦(VAL)或缬沙坦加氢氯噻嗪(VAL / HYCT)联合快速药物治疗的有效性和安全性是最常见的心血管危险因素。 4个月研究期的结果显示,在中年1059位患者中使用VAL或VAL / HYCT进行治疗可显着降低收缩压和舒张压。平均收缩压和舒张压分别从161.2(±16.5)和92.9(±9.5)mmHg降低到136.1(±12.5)和81.6(±7.8)mmHg。仅在少数患者中观察到副作用:血清肌酐升高(4.6%),HbA1c升高(1%)和血清钾值(0.3%)。可以得出结论,VAL或VAL / HYCT是安全且非常有效的有效降压药。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号